CL2023002998A1 - Compuestos de tienopirrol - Google Patents

Compuestos de tienopirrol

Info

Publication number
CL2023002998A1
CL2023002998A1 CL2023002998A CL2023002998A CL2023002998A1 CL 2023002998 A1 CL2023002998 A1 CL 2023002998A1 CL 2023002998 A CL2023002998 A CL 2023002998A CL 2023002998 A CL2023002998 A CL 2023002998A CL 2023002998 A1 CL2023002998 A1 CL 2023002998A1
Authority
CL
Chile
Prior art keywords
compounds
present description
lupus erythematosus
pharmaceutical compositions
thienopyrrole compounds
Prior art date
Application number
CL2023002998A
Other languages
English (en)
Inventor
Scott E Lazerwith
Michael L Mitchell
Scott D Schroeder
Yasamin Moazami
Eda Y Canales
Stephen E Ammann
Daniel G Shore
Weng K Chang
Henok H Kinfe
Christopher J Swank
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2023002998A1 publication Critical patent/CL2023002998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se relaciona generalmente con ciertos compuestos, composiciones farmacéuticas que comprenden dichos compuestos y métodos para preparar y usar dichos compuestos y composiciones farmacéuticas. Los compuestos y composiciones proporcionados en la presente descripción pueden usarse para el tratamiento o prevención de una enfermedad autoinmunitaria y/o condición inflamatoria, que incluye el lupus eritematoso sistémico y lupus eritematoso cutáneo
CL2023002998A 2021-04-16 2023-10-06 Compuestos de tienopirrol CL2023002998A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176109P 2021-04-16 2021-04-16
US202163216418P 2021-06-29 2021-06-29
US202263305610P 2022-02-01 2022-02-01

Publications (1)

Publication Number Publication Date
CL2023002998A1 true CL2023002998A1 (es) 2024-04-26

Family

ID=81580723

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002998A CL2023002998A1 (es) 2021-04-16 2023-10-06 Compuestos de tienopirrol

Country Status (16)

Country Link
US (2) US11661431B2 (es)
EP (1) EP4323369A1 (es)
JP (1) JP2024513945A (es)
KR (1) KR20230171469A (es)
AU (1) AU2022257039A1 (es)
BR (1) BR112023021107A2 (es)
CA (1) CA3214808A1 (es)
CL (1) CL2023002998A1 (es)
CO (1) CO2023013397A2 (es)
CR (1) CR20230478A (es)
DO (1) DOP2023000219A (es)
IL (1) IL307203A (es)
MX (1) MX2023012110A (es)
PE (1) PE20240919A1 (es)
TW (1) TW202302598A (es)
WO (1) WO2022221642A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327574A (zh) * 2021-09-10 2023-07-16 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
JP5390186B2 (ja) 2005-08-12 2014-01-15 ユナイテッド ステイツ ガバメント アズ レプリゼンティッド バイ ザ セクレタリー オブ ザ ユナイテッド ステイツ アーミー アンド ザ ユーエス アーミー メディカル リサーチ アンド マティリ 広い抗菌スペクトルを有する抗菌性化合物
AU2006279537A1 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as TPO mimetics
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
WO2008008912A1 (en) * 2006-07-14 2008-01-17 Genelabs Technologies, Inc. Antiviral agents
DK2119703T3 (da) 2007-01-15 2013-01-14 Santen Pharmaceutical Co Ltd Nyt indolderivat med inhiberende virkning på I-B-kinase.
MX2009009792A (es) 2007-03-12 2009-09-23 Cytopia Res Pty Ltd Compuestos de fenil amino pirimidina y usos de los mismos.
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2010036905A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
AU2012262014B2 (en) 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators
EP2713737B1 (en) 2011-06-01 2016-04-20 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR101452579B1 (ko) 2012-08-17 2014-10-21 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
SI3057964T1 (sl) 2013-10-14 2020-03-31 Eisai R&D Management Co., Ltd. Selektivno substituirane spojine kinolina
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
CN112707893B (zh) 2015-03-30 2023-10-31 特殊治疗有限公司 作为usp30抑制剂的1-氰基吡咯烷化合物
US20180312493A1 (en) 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
EP3889145B1 (en) 2015-12-17 2024-02-21 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
RS62322B1 (sr) 2016-04-15 2021-10-29 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
CA3021947A1 (en) 2016-04-26 2017-11-02 Sumitomo Dainippon Pharma Co., Ltd. Substituted purine derivative
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EA038972B1 (ru) 2016-07-30 2021-11-16 Бристол-Маерс Сквибб Компани Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
MX2019001096A (es) 2016-08-08 2019-07-04 Merck Patent Gmbh Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
AU2017323584C1 (en) 2016-09-09 2020-09-17 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
KR102519535B1 (ko) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
EP3655401B1 (en) 2017-07-18 2023-09-06 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
KR20200036913A (ko) 2017-08-04 2020-04-07 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
JP2021035910A (ja) 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
EP3707140B1 (en) 2017-11-08 2021-10-13 Council of Scientific and Industrial Research Purine based compounds as toll-like receptor 9 antagonists
KR20200086709A (ko) 2017-11-14 2020-07-17 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
BR112020011668A2 (pt) 2017-12-15 2020-11-17 Bristol-Myers Squibb Company compostos de éter de indol substituído
JP7289301B2 (ja) 2017-12-18 2023-06-09 ブリストル－マイヤーズ スクイブ カンパニー ４－アザインドール化合物
CA3086172A1 (en) 2017-12-19 2019-06-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
KR20200101402A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 치환된 인돌 화합물
CA3085761A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists
CA3085346A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
BR112020011984A2 (pt) 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
WO2019123294A2 (en) 2017-12-22 2019-06-27 Novartis Ag Novel uses of pyrazolo piperidine derivatives
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
MX2021000093A (es) 2018-07-31 2021-03-25 Merck Patent Gmbh Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP2022505707A (ja) 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
US20220213099A1 (en) 2019-05-07 2022-07-07 Bristol-Myers Squibb Company Prodrug compounds
KR20220006571A (ko) 2019-05-09 2022-01-17 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
US20220241410A1 (en) 2019-05-23 2022-08-04 The University Of Montana Vaccine adjuvants based on tlr receptor ligands
EP4041730A1 (en) * 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
JP2023501956A (ja) 2019-11-01 2023-01-20 ブリストル－マイヤーズ スクイブ カンパニー 置換ピラゾール化合物
JP2023526304A (ja) 2020-05-14 2023-06-21 メルク ヘルスケア コマンディトゲゼルシャフト アウフ アクティーン コロナウイルス感染症治療のためのｔｌｒ７／８拮抗薬
MX2022015760A (es) 2020-06-11 2023-01-19 Bristol Myers Squibb Co Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo.
US20230310409A1 (en) 2020-06-22 2023-10-05 Bristol-Myers Squibb Company Treating rheumatoid arthritis
WO2022022489A1 (zh) 2020-07-27 2022-02-03 江苏恒瑞医药股份有限公司 吲哚稠环类衍生物、其制备方法及其在医药上的应用
CN114075219B (zh) 2020-08-14 2023-11-14 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
CN114075212B (zh) 2020-08-14 2023-05-12 江苏恒瑞医药股份有限公司 稠合三环类衍生物、其制备方法及其在医药上的应用
EP4200015A1 (en) 2020-08-19 2023-06-28 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as inhibitors of tlr9
MX2023006193A (es) 2020-11-26 2023-06-09 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
WO2022140325A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds
EP4267559A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds

Also Published As

Publication number Publication date
CR20230478A (es) 2023-11-30
AU2022257039A1 (en) 2023-10-05
KR20230171469A (ko) 2023-12-20
TW202302598A (zh) 2023-01-16
US11661431B2 (en) 2023-05-30
WO2022221642A1 (en) 2022-10-20
EP4323369A1 (en) 2024-02-21
PE20240919A1 (es) 2024-04-30
MX2023012110A (es) 2023-10-24
CA3214808A1 (en) 2022-10-20
CO2023013397A2 (es) 2023-10-30
JP2024513945A (ja) 2024-03-27
BR112023021107A2 (pt) 2023-12-12
US20230365594A1 (en) 2023-11-16
US20220389034A1 (en) 2022-12-08
DOP2023000219A (es) 2023-11-15
IL307203A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CO2023013397A2 (es) Compuestos de tienopirrol
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2020002919A1 (es) Inhibidores de mcl-1
CO2020015156A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos referencia cruzada a una solicitud relacionada
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
UY37098A (es) Moduladores de ror-gamma
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2021004999A (es) Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos.
CL2022002695A1 (es) Inhibidores de rip1k
EA201690810A1 (ru) Мягкие пастилки, содержащие экстракт куркумы
BR112017010933A2 (pt) composição farmacêutica
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2016002400A1 (es) Formulación para higiene personal
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
AR103607A1 (es) Composición farmacéutica para la aplicación tópica en el conducto auditivo
DOP2018000211A (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.